SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

April 17, 2014 07:45 ET

Sirona Engages Torrey Hills Capital

VANCOUVER, BC--(Marketwired - April 17, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") is pleased to announce that it has retained the services of San Diego Torrey Hills Capital, Inc. ("Torrey Hills "), a Rancho Santa Fe, California based investor relations firm, to provide market awareness and investor relations services to the Company, subject to TSX Venture Exchange acceptance. Torrey Hills will develop and manage a comprehensive finance and investor relations campaign for the Company including building and maintaining an investor audience, increasing awareness of the Company in the investor community and coordinating communication with management and investment professionals.

"Torrey Hills Capital brings a track record of success working with companies like Sirona Biochem. We are looking forward to their support in introducing and educating our target audiences about Sirona's unique value proposition," states Neil Belenkie, CEO of Sirona Biochem.

"We are excited to partner with Sirona Biochem," commented Cliff Mastricola, President of Torrey Hills Capital. "Management has a proven record of success and we really like what the Company is doing with its proprietary chemistry technology to enhance the stability of carbohydrate-based molecules. As a result, we believe the investment community will have an interest in the story."

In addition to the stock options described below, Torrey Hills, through its officers, directors, employees, and consultants, controls approximately twenty-five thousand common shares of stock of the Company, which were purchased on the open market. 

Under the terms of the agreement, the Company will pay Torrey Hills US$4,000 per month for a period of six months and grant Torrey Hills 400,000 stock options for a period of three years at an exercise price of $0.16 per share, with vesting in accordance with TSX Venture Exchange policies and the Company's Stock Option Plan.

About San Diego Torrey Hills Capital

Torrey Hills Capital is a leading investor relations firm focused on introducing management teams and marketing small and microcap companies to investors in more than 50 cities across the United States and Canada. We organize one-on-one and group meetings between our clients and our network of institutional, retail, and private investors, as well as with analysts and newsletter writers. Our investors attend relevant industry conferences and participate in client site visits. Our comprehensive feedback and ongoing marketing efforts post-meetings are second to none.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

  • For more information regarding this press release, contact:
    Christopher Hopton
    Sirona Biochem Corp.
    Phone: 1.604.282.6064